Genexis Biotech Raises INR 4 Cr in Seed Round Led by GVFL

The funding will support the expansion of Genexis Biotech’s manufacturing infrastructure.

Vadodara-based bio-manufacturing startup Genexis Biotech has secured INR 4 crore in a seed funding round led by GVFL, with additional participation from Benzai10.

The funding will support the expansion of Genexis Biotech’s manufacturing infrastructure.

The company plans to scale its bioreactor capacity and build downstream processing capabilities. Funds will also be directed toward launching new recombinant proteins and enzymes and enhancing compliance, sales, and distribution functions.

Genexis Biotech specializes in developing animal-origin-free recombinant proteins through precision fermentation. Its applications span across biopharma, food-tech, and cell culture sectors. The company currently operates a certified Class 10,000 facility and is in the process of setting up a GMP-compliant unit.

The startup has introduced recombinant peptidases such as amino peptidase and enterokinase. As part of its upcoming product pipeline, it plans to launch recombinant transferrin and albumin.

In the last year, Genexis has partnered with pharmaceutical and biotech firms. It signed a Memorandum of Understanding (MoU) with the Gujarat government and has received client orders for alternative protein formulations. Genexis also participated in Global Bio-India 2024 to showcase its product portfolio.

Looking ahead, the company aims to enter the regulated biotech export market. It plans to develop encapsulated formulations for the cosmetics industry and collaborate with Contract Development and Manufacturing Organizations (CDMOs), academic labs, and biopharma companies.

GVFL has backed the startup as part of its broader investment thesis in deeptech and biotech sectors.

Stay tuned for more such updates on Digital Health News